Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Brexit

Set Alert for Brexit

'Get Your Skates On', UK Firms Planning M&A Warned

UK pharma groups planning M&A deals ‘must get their skates on’ and begin filing now if they want to benefit from the EU’s review process before the Brexit transition period ends on 31 December.

Companies Regulation M & A

Brexit Finally Here But Uncertainty Not Over For Biopharma

A free trade deal needs to be negotiated in record time and UK life sciences must face up to diverging from the EU.

Europe United Kingdom Brexit

Latest From Brexit

UK To Diverge On Biosimilar Data Requirements

The UK regulator wants to be a “catalyst for change” in reducing regulatory burdens, saying that better regulation based on science is in everyone’s interest.

United Kingdom Europe

Not Too Late? German Industry Presses For EU MRA With Post-Brexit UK

BVMed says the EU and the UK should set up a system of mutual recognition of medical device regulation to kick in when the UK’s EU exit transition period ends on 31 December. 

EU Regulation

‘No Turning Back’ On Regulatory Changes at UK MHRA

The UK medicines regulator has a “unique opportunity” to evaluate the systems it operates and to “do things differently", according to its long-term interim head, June Raine.

United Kingdom Regulation

Brexit: UK To Change Drug Import And Export Rules From 2021

New guidance documents issued by the UK regarding medicines regulation after the end of the Brexit transition period cover the import of medicinal products from countries on an approved list, trade in APIs between the UK and third countries, and the acceptance of batch testing under existing mutual recognition agreements.

United Kingdom Europe

UK Explains Post-Brexit Pediatric Study Processes

The Medicines and Healthcare products Regulatory Agency has outlined the various common scenarios that may occur when companies submit a UK pediatric investigation plan after the Brexit transition period has expired.

Pediatrics Brexit

The UK’s Future As Innovator In A Post-Brexit, Post-Coronavirus World

Regulatory flexibilities combined with experience in cell and gene therapy and the wider use of technologies such as AI could help to keep the post-Brexit UK at the forefront of innovation in the life sciences. A UK regulatory conference will be discussing these and other key issues next week.

United Kingdom Brexit

UK Regulator Explains Data Requirements For Converted EU Approvals

In another of the many guidances it has issued on medicines regulation in the post-Brexit UK, the MHRA explains the additional information it will need from companies whose EU marketing authorizations are converted into national MAs in January 2021, and the new labeling requirements for those products. 

United Kingdom Brexit

UK Offers Pragmatic Approach To Safety Reporting From Jan 2021

The UK’s approach to pharmacovigilance system requirements in the post-Brexit transition period will allow companies to leverage some of the existing structures put in place for EU systems.

United Kingdom Brexit

Gloom Over Prospects For Brexit Trade Deal

With time running out on the UK-EU trade deal negotiations, the UK life sciences industry looks at the fine print of the new guidance on medicines regulation and explains why a mutual recognition agreement is urgently needed. 

Brexit Trade
See All
UsernamePublicRestriction

Register